• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/27/25 4:10:08 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    8-K
    0001468748false0001468748dei:FormerAddressMember2025-03-272025-03-2700014687482025-03-272025-03-27

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 27, 2025

     

     

    Kodiak Sciences Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38682

    27-0476525

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1250 Page Mill Rd

     

    Palo Alto, California

     

    94304

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 650 281-0850

     

    Kodiak Sciences Inc.

    1200 Page Mill Rd

    Palo Alto, California 94304

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $0.0001

     

    KOD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On March 27, 2025, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2024 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

    In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in any such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit Number

    Description

    99.1

    Press Release published by Kodiak Sciences Inc. dated March 27, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    KODIAK SCIENCES INC.

     

     

     

     

    Date:

    March 27, 2025

    By:

    /s/ Victor Perlroth

     

     

     

    Victor Perlroth, M.D.
    Chief Executive Officer

     


    Get the next $KOD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    8/14/2025$15.00Underweight → Neutral
    Analyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    11/17/2023$7.00 → $12.00Equal Weight → Overweight
    CapitalOne
    7/27/2023$15.00 → $4.00Buy → Neutral
    UBS
    7/25/2023Buy → Neutral
    Chardan Capital Markets
    7/25/2023Neutral → Underweight
    JP Morgan
    More analyst ratings

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kodiak Sciences upgraded by Analyst with a new price target

    Analyst upgraded Kodiak Sciences from Underweight to Neutral and set a new price target of $15.00

    8/14/25 8:06:05 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Jefferies with a new price target

    Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00

    12/9/24 7:57:06 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Kodiak Sciences with a new price target

    H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00

    9/5/24 7:49:18 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

    PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets –tarcocimab, KSI-501 and KSI-101– underscoring their transformative potential in retinal disease treatment," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to inflammation (ME

    8/13/25 4:00:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences to Host Investor R&D Day on July 16, 2025

    PALO ALTO, Calif.  , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025, from 4:00 pm ET to 5:30 pm ET. The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of Kodiak's senior leadership team complemented by distinguished industry experts. A live webcast of this event will be available to investors and other interested parties. Registration for

    7/10/25 8:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

    PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion leaders will present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, Brazil on Friday, June 27, 2025. "We are excited to participate in this year's IOIS meeting and connect with leading experts in ocular inflammation to help advance care for patients with macular edema caused by inflammation," said Pablo Velazquez-Martin, MD, Chief

    6/25/25 4:45:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    SEC Filings

    View All

    SEC Form 10-Q filed by Kodiak Sciences Inc

    10-Q - Kodiak Sciences Inc. (0001468748) (Filer)

    8/13/25 4:11:10 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kodiak Sciences Inc. (0001468748) (Filer)

    8/13/25 4:00:37 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Kodiak Sciences Inc

    8-K - Kodiak Sciences Inc. (0001468748) (Filer)

    6/3/25 4:29:59 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Borgeson John A.

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:33:23 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chairman and CEO Perlroth Victor

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:30:46 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/2/25 5:08:03 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Financials

    Live finance-specific insights

    View All

    Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

    PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

    3/26/24 6:15:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

    PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

    2/23/22 6:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Leadership Updates

    Live Leadership Updates

    View All

    Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

    PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

    9/17/24 4:05:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

    SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

    12/3/20 11:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/24 4:23:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    1/26/24 11:49:38 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/23 4:19:55 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care